First-Line Nivolumab Plus Chemo Approved for Bladder Cancer

(MedPage Today) -- The FDA approved the PD-1 immune checkpoint inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, the agency announced...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news